2 completed, 1 active not recruiting, 1 terminated, 1 unknown. 4 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 1, Completed 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Trabedersen: new trials by email Literature Review of Trabedersen trials Research Report on Trabedersen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1 Trabedersen, Pembrolizumab - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | University of Nebraska | 45 | 2025-05-12 | 2026-09-25 |
| OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer Atezolizumab, Biopsy, Biospecimen Collection - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Withdrawn | University of Washington | 2023-12-01 | 2023-08-25 | |
| A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects OT-101, Artemisinin, Placebo - COVID-19 | Phase 2 | Unknown | Oncotelic Inc. | 18 | 2021-04-01 | 2021-03-16 |
| Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma trabedersen, temozolomide, Drug delivery system for administration of AP 12009 - Anaplastic Astrocytoma, Glioblastoma | Phase 3 | Terminated | Isarna Therapeutics GmbH | 27 | 2008-12-01 | 2014-11-14 |
| Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2 AP 12009 - Pancreatic Neoplasms, Melanoma | Phase 1 | Completed | Isarna Therapeutics GmbH | 62 | 2005-01-01 | 2019-02-15 |
| Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma AP 12009 10 µM, AP 12009 80 µM, temozolomide or PCV - Glioblastoma, Anaplastic Astrocytoma | Phase 2 | Completed | Isarna Therapeutics GmbH | 141 | 2003-04-01 | 2013-12-03 |
Astrocytoma (2) · Brain Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Glioblastoma (2) · Neoplasms (2) · COVID-19 (1) · Camurati-Engelmann Syndrome (1) · Colorectal Neoplasms (1) · Glioma (1) · Lung Neoplasms (1) · Melanoma (1) · Pancreatic Neoplasms (1)
Isarna Therapeutics GmbH (3) · Oncotelic Inc. (1) · University of Nebraska (1) · University of Washington (1)
Germany (3) · United States (3) · Austria (2) · Brazil (2) · India (2) · Russia (2) · Argentina (1) · Canada (1) · France (1) · Georgia (1) · Hungary (1) · Israel (1) · Mexico (1) · Poland (1) · South Korea (1)
Helmut Oettle, MD (1) · Omar Abughanimeh, MBBS (1) · Rafael Santana-Davila (1) · Rolando Del Maestro, MD, PhD (1) · Ulrich Bogdahn, MD (1) · Vuong Trieu, PhD (1)